Cardioprotective Effect of Metformin on the level of micro RNAs, mir-222, mir-195, mir-21a, in type 1 diabetes patients

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200217046520N1

Enrollment

Registered

2020-03-19

Start date

2020-05-09

Completion date

Unknown

Last updated

2020-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Type 1 diabetes. Condition 2: Cardiovascular disease.

Interventions

Intervention group: 28 Patients 19-45 years old with type 1 diabetes referred to Loghman Hospital Endocrine Clinic. Plasma levels of miR-222, miR-195, miR-21a are first measured, then patients will be

Eligibility

Sex/Gender

All

Age

19 Years to 45 Years

Inclusion criteria

Inclusion criteria: age 19 to 45 years insulin-treated for the past three months the patient's blood sugar has been controlled HbA1c ranged from 6/5 to 7/5 lack of cardiovascular disease it's been 5 years since diabetes informed consent

Exclusion criteria

Exclusion criteria: pregnancy or pregnancy intent in the near future Kidney failure (creatinine equal to or greater than 1/3) history of cardiovascular disease history of intraocular injection Glycated haemoglobin greater than 7/5

Design outcomes

Primary

Measure	Time frame
Plasma levels of micro RNA 222 before and after metformin administration. Timepoint: Plasma level of micro RNA 222 at baseline and 12 weeks after metformin administration. Method of measurement: blood test.;Plasma levels of micro RNA 195 before and after metformin administration. Timepoint: Plasma level of micro RNA 195 at baseline and 12 weeks after metformin administration. Method of measurement: blood test.;Plasma levels of micro RNA 21a before and after metformin administration. Timepoint: Plasma level of micro RNA 21a at baseline and 12 weeks after metformin administration. Method of measurement: blood test.	—

Measure

Time frame

Plasma levels of micro RNA 222 before and after metformin administration. Timepoint: Plasma level of micro RNA 222 at baseline and 12 weeks after metformin administration. Method of measurement: blood test.;Plasma levels of micro RNA 195 before and after metformin administration. Timepoint: Plasma level of micro RNA 195 at baseline and 12 weeks after metformin administration. Method of measurement: blood test.;Plasma levels of micro RNA 21a before and after metformin administration. Timepoint: Plasma level of micro RNA 21a at baseline and 12 weeks after metformin administration. Method of measurement: blood test.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMina Moghtaderi

Shahid Beheshti University of Medical Sciences

Minamoghtaderi@yahoo.com+98 21 8877 0065

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026